Two Sigma Investments’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.3M Buy
65,000
+56,300
+647% +$2.63M ﹤0.01% 2362
2025
Q4
$257K Sell
8,700
-2,300
-21% -$62.5K ﹤0.01% 3654
2025
Q3
$284K Buy
+11,000
New +$307K ﹤0.01% 3238
2022
Q1
Sell
-75,200
Closed -$19.1M 3718
2021
Q4
$19.1M Sell
75,200
-2,400
-3% -$702K 0.04% 493
2021
Q3
$29.9M Sell
77,600
-39,200
-34% -$14.5M 0.07% 324
2021
Q2
$27.4M Sell
116,800
-52,600
-31% -$9.4M 0.06% 388
2021
Q1
$22.2M Buy
+169,400
New +$24.5M 0.06% 389

Other funds holding MRNA

Two Sigma Investments's MRNA Position: Q1 2026 in Review

Two Sigma Investments increased its Moderna (MRNA) stake by 24% in Q1 2026, buying an estimated $81.4M and bringing the position to 9,086,404 shares worth $462M. The position accounts for 0.37% of the portfolio, ranked #42.

Two Sigma Investments first reported a position in MRNA in Q2 2019 and has held it in 18 quarters since. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Two Sigma Investments held 9,086,404 shares of Moderna worth $462M as of Q1 2026.
  • Two Sigma Investments bought 1,744,308 Moderna shares in Q1 2026, an estimated $81.4M.
  • Moderna made up 0.37% of Two Sigma Investments's portfolio in Q1 2026, its #42 holding.
  • Two Sigma Investments first reported a position in Moderna in Q2 2019 and has held it in 18 quarters since.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.